You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

Details for New Drug Application (NDA): 211243


✉ Email this page to a colleague

« Back to Dashboard


NDA 211243 describes SPRAVATO, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the SPRAVATO profile page.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this compound. Additional details are available on the esketamine hydrochloride profile page.
Summary for 211243
Tradename:SPRAVATO
Applicant:Janssen Pharms
Ingredient:esketamine hydrochloride
Patents:7
Suppliers and Packaging for NDA: 211243
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SPRAVATO esketamine hydrochloride SPRAY;NASAL 211243 NDA Janssen Pharmaceuticals Inc. 50458-028 50458-028-02 2 BLISTER PACK in 1 KIT (50458-028-02) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)
SPRAVATO esketamine hydrochloride SPRAY;NASAL 211243 NDA Janssen Pharmaceuticals Inc. 50458-028 50458-028-03 3 BLISTER PACK in 1 KIT (50458-028-03) / 1 VIAL, SINGLE-USE in 1 BLISTER PACK / .2 mL in 1 VIAL, SINGLE-USE (50458-028-00)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY;NASALStrengthEQ 28MG BASE
Approval Date:Mar 5, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 5, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
Patent:⤷  Sign UpPatent Expiration:Sep 10, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
Patent:⤷  Sign UpPatent Expiration:Sep 10, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.